Australia markets closed

Shield Therapeutics plc (STX.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
1.5500-0.1000 (-6.06%)
At close: 05:07PM BST
Currency in GBp

Valuation measures4

Market cap (intra-day) 12.12M
Enterprise value 4.30M
Trailing P/E 53.33
Forward P/E 65.36
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.19
Price/book (mrq)0.45
Enterprise value/revenue 0.69
Enterprise value/EBITDA -0.12

Trading information

Stock price history

Beta (5Y monthly) 0.84
52-week change 3-79.33%
S&P500 52-week change 322.38%
52-week high 312.8500
52-week low 31.0630
50-day moving average 31.9330
200-day moving average 36.2285

Share statistics

Avg vol (3-month) 37.16M
Avg vol (10-day) 38.46M
Shares outstanding 5782.06M
Implied shares outstanding 6832.51M
Float 8373.94M
% held by insiders 156.18%
% held by institutions 115.81%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 June 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-266.29%

Management effectiveness

Return on assets (ttm)-42.79%
Return on equity (ttm)-146.62%

Income statement

Revenue (ttm)7.4M
Revenue per share (ttm)0.02
Quarterly revenue growth (yoy)65.80%
Gross profit (ttm)N/A
EBITDA -28.28M
Net income avi to common (ttm)-48.88M
Diluted EPS (ttm)-0.1200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)13.59M
Total cash per share (mrq)0.02
Total debt (mrq)5.77M
Total debt/equity (mrq)21.30%
Current ratio (mrq)2.95
Book value per share (mrq)0.04

Cash flow statement

Operating cash flow (ttm)-27.56M
Levered free cash flow (ttm)-19.29M